Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 1Q Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

1Q Financial Report: Merck

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck

1Q Revenues: $5.4 billion (+1%)

1Q Earnings: $1.5 billion (+11%)

Comments: Zocor and Singulair performed well in the quarter. Worldwide sales of Singulair were $801 million, up 9%. Worldwide Zocor sales were $1.1 billion, down 4%, but U.S. sales were up 13%. Strong results from partnerships drove earnings for the quarter. As reported by the Merck/Schering-Plough partnership, global sales of Zetia and Vytorin reached $793 million. Global sales by the Merck/Schering-Plough cholesterol partnership of Zetia reached $415 million in the quarter, up 25%. The company received FDA approval for Rotateq in the quarter. R&D expenses were $942 million for the quarter, up 11%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters